Saccharomyces Boulardii is a type of probiotic yeast that belongs to the Saccharomyces cerevisiae family. However, an important distinction to make is that S. boulardii is genetically and functionally distinct from brewer's yeast (S. cerevisiae) This particular strain is a tropical yeast first isolated from lychee and mangosteen fruit peel in 1923 by French scientist Henri Boulard[i].
Probiotics are commonly referred to as "good bacteria" as they mimic the role of beneficial bacteria that are naturally present in our bodies. They aid in combating harmful bacteria and promote digestion and absorption of nutrients. Saccharomyces boulardii is a type of probiotic with a significant distinction: it is not a type of bacteria but rather a yeast that performs the same probiotic functions in the body. Acidic environments, high temperatures, bile, and digestive enzymes do not deactivate it, which means it can reach the intestines alive. It has many benefits to the body and can help improve, and prevent many cases of intestinal distress. Read on to see how S. boulardii can benefit you if supplemented.
Its probiotic properties encompass a broad range of activities, such as enhancing gut health, generating antimicrobial effects, boosting the immune system and preventing inflammation. S. boulardii is primarily employed for managing gastrointestinal disorders, particularly diarrhoea. Read on to discover the benefits, adverse effects, and precautions associated with S. boulardii, as well as the key factors to consider when selecting an S. boulardii supplement.
This article discusses the uses, side effects, and precautions of S. boulardii. It also covers what to look for in a good S. boulardii supplement.
Saccharomyces boulardii is commonly used for gastrointestinal disorders such as the following[ii]:
Traveller’s diarrhoea
Antibiotic-associated diarrhoea
Irritable bowel syndrome (IBS)
Crohn’s disease
Ulcerative colitis
This occurs when a person drinks contaminated food or water, usually while in a different country. Several studies have found significant benefits in reducing and helping to resolve cases of traveller’s diarrhoea[iv][v][iii].
According to a 2020 review, there is evidence that S. boulardii may help prevent antibiotic-associated diarrhoea by helping to restore a person’s gut flora after the medication has been taken. As it is yeast, antibiotics do not kill it, which means a person can take antibiotics and S. boulardii at the same time[vii][vi].
Saccharomyces boulardii is a widely used fungal probiotic in treating various digestive diseases, including irritable bowel syndrome (IBS), which is often used as an umbrella term for a collection of bowel-related symptoms. Saccharomyces boulardii is thought to improve IBS by helping to restore proper movement of the gut wall, thus reducing IBS symptoms such as spasms, gas and diarrhoea[viii].
Intestinal permeability is a term describing the control of material passing from inside the gastrointestinal tract through the cells lining the gut wall. This process is natural, however in disease states, unwanted substances may pass into the blood stream and further inflammation in the body. This is often referred to as ‘leaky gut’. As seen in a study, patients with Crohn's disease in remission, S. boulardii resulted in improvements in intestinal permeability, while those receiving placebo experienced an increase in permeability over the study period [vi].
Several studies have seen improvements in conditions relating to IBD, including Crohn’s disease and ulcerative colitis[xi] [xii][ix][x].
Evidence supports use of S. boulardii whilst taking antibiotics to negate negative prescription. In a study of 193 patients, administration of S. boulardii (1000 mg per day) from the beginning of antibiotic treatment and continued for 3 days after the course, significantly prevented the occurrence of diarrhoea compared to placebo [vii].
In a study, a daily supplement of the probiotic S boulardii (1000 mg per day) for 3 months, resulted in a marked improvement in cardiovascular health markers compared with those taking a placebo [viii].
Candida is yeast naturally occurring in our bodies, however in cases of overgrowth, it can cause disease. S. boulardii produces capric, caprylic and caproic acids which can help to prevent the proliferation of candida yeasts. A study found S boulardii to reduce candida infections and to lessen the inflammatory host response associated with symptoms of candida overgrowth [ix] [x].
Lowering High cholesterol
Combating Helicobacter pylori (H. pylori) infection
Combating Clostridium difficile infection [xiii] [xiv]
When it comes to safety, there are certain considerations that should be taken into account, such as pregnancy, breastfeeding, children, older adults, individuals with digestive tract disorders or weakened immune systems, and those with yeast allergies. Common side effects of S. boulardii include bloating and flatulence, while a rare but severe side effect may occur in people with multiple severe medical conditions or central venous catheters, leading to fungal blood infections[xv] [xvi].
If an antifungal medication needs to be taken concurrently with S. boulardii, it is suggested that the two be separated by at least four hours apart[xvii].
Irritable Bowel Syndrome , Diarrhoea , Pelvic Inflammatory Disease , Ulcerative Colitis , Crohn's Disease , Cholesterol , Helicobacter Pylori , Colitis , Candida , Leaky Gut , Mood Regulation
[i] Malgoire JY, Bertout S, Renaud F, Bastide JM, Mallié M (March 2005). "Typing of Saccharomyces cerevisiae clinical strains by using microsatellite sequence polymorphism". Journal of Clinical Microbiology. 43 (3): 1133–7.
[ii] Lazo-Vélez MA, Serna-Saldívar SO, Rosales-Medina MF, Tinoco-Alvear M, Briones-García M. Application of Saccharomyces cerevisiae var. boulardii in food processing: a review. J Appl Microbiol. 2018;125(4):943-951.
[iii] McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202-2222.
[iv] Kollaritsch H, Holst H, Grobara P, Wiedermann G. Prophylaxe der Reisediarrhöe mit Saccharomyces boulardii. Ergebnisse einer plazebokontrollierten Doppelblindstudie [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study]. Fortschr Med. 1993 Mar 30;111(9):152-6. German.
[v] Bleichner G, Bléhaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med. 1997 May;23(5):517-23.
[vi] Szajewska H, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015;42(7):793-801.
[vi] Garcia, V. E. De Lourdes, M. Oswaldo, H. et al. (2008) ‘Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission’. Scand J Gastroenterol. 2008;43(7):842-8.
[vii] Surawicz, C.M. Elmer, G.W. Speelman, P. et al. (1989) ‘Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii: a prospective study’. Gastroenterology. 96: 981–8.
[vii] Kaźmierczak-Siedlecka K, Ruszkowski J, Fic M, Folwarski M, Makarewicz W. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. Curr Microbiol. 2020 Sep;77(9):1987-1996.
[viii] Costanza, A.C.Moscavitch, S.D. Faria Neto, H.C. et al. (2015) ‘Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized,double-blind, placebo-controlled pilot trial’. Int J Cardiol. 179:348–50.
[viii] Gu, Y., Wang, C., Qin, X., Zhou, B., Liu, X., Liu, T., Xie, R., Liu, J., Wang, B., & Cao, H. (2022). Saccharomyces boulardii, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota. Pharmacological Research, 181, 105453.
[ix] Murzyn A et al. (2010) ‘Capric Acid Secreted by S. boulardiiInhibits C’. Albicans Plos One 2010 5(8):
[ix] Sivananthan K, Petersen AM. Review of Saccharomyces boulardii as a treatment option in IBD. Immunopharmacol Immunotoxicol. 2018;40(6):465-475.
[x] Murzyn, A. Krasowska, A. et al. (2010) ‘The effect of Saccharomyces boulardii on Candida albicans-infected human intestinal cell lines Caco-2 and Intestin 407’ FEMS Microbiology Letters. 310 (1) 17-23.
[x] Sivananthan K, Petersen AM. Review of Saccharomyces boulardii as a treatment option in IBD. Immunopharmacol Immunotoxicol. 2018;40(6):465-475.
[xii] Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis
Saskia Thomas, Diana Metzke, Jürgen Schmitz, Yvonne Dörffel, and Daniel C. Baumgart
American Journal of Physiology-Gastrointestinal and Liver Physiology 2011 301:6, G1083-G1092
[xiii] Ryan JJ, Hanes DA, Schafer MB, Mikolai J, Zwickey H. Effect of the Probiotic Saccharomyces boulardii on Cholesterol and Lipoprotein Particles in Hypercholesterolemic Adults: A Single-Arm, Open-Label Pilot Study. J Altern Complement Med. 2015;21(5):288-293.
[xiv] Kaźmierczak-Siedlecka K, Ruszkowski J, Fic M, Folwarski M, Makarewicz W. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. Curr Microbiol. 2020;77(9):1987-1996.
[xv] Williams NT. Probiotics. Am J Health Syst Pharm. 2010;67(6):449-458.
[xvi] McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202-2222.
[xvii] McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202-2222.
Understand the unique benefits of essential fatty acids, including their benefits, where y...
Explore the world of medicinal mushrooms and their remarkable medicinal properties. We are...
We take a look at the benefits of organic growing methods on nutrition, health, soil quali...